Funding also became an issue in the Seroxat Group Litigation Order (GLO). More than 500 claimants joined the GLO against pharmaceutical giant GlaxoSmithKline UK, alleging to have suffered withdrawal effects when reducing, discontinuing or attempting to discontinue use of the antidepressant Seroxat. It was alleged that such suffering amounted to personal injury.
http://www.thelawyer.com/cases-in-point/1010834.article
According to a lawyer close to the case the claimant numbers have fallen dramatically as a result of the withdrawal of legal aid. This was made particularly contentious because the firm used to represent the claimants, Cardiff-headquartered Hugh James, revised down the considered success of the case, forming the basis for the withdrawal of state funding.
It is understood that 125 claimants will continue to pursue the action but that they will be looking for a new law firm to represent them. Meanwhile, a group of the remaining claimants are appealing the Legal Services Commission’s decision to cancel the legal aid.
http://www.thelawyer.com/cases-in-point/1010834.article
It is understood that 125 claimants will continue to pursue the action but that they will be looking for a new law firm to represent them. Meanwhile, a group of the remaining claimants are appealing the Legal Services Commission’s decision to cancel the legal aid.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.